Research ArticleCancer

RANKL blockade prevents and treats aggressive osteosarcomas

See allHide authors and affiliations

Science Translational Medicine  09 Dec 2015:
Vol. 7, Issue 317, pp. 317ra197
DOI: 10.1126/scitranslmed.aad0295

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

OutRANKing osteosarcoma

Osteosarcoma is the most common primary bone cancer, and it can be difficult to treat, especially in patients with metastatic disease. Chen et al. developed a series of genetically engineered mouse models of osteosarcoma and used these models to dissect the role of receptor activator of nuclear factor κB ligand (RANKL) signaling in the progression of this disease. The authors also showed that denosumab, an antibody against RANKL that is already used in patients with some bone diseases, is effective in mouse models of osteosarcoma and is a viable candidate for future testing in human patients.